STAAR Surgical Company (STAA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
STAA Revenue Growth
Revenue Breakdown (FY 2024)
STAA's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
STAA Revenue Analysis (2014–2025)
As of May 8, 2026, STAAR Surgical Company (STAA) generated trailing twelve-month (TTM) revenue of $239.4 million, reflecting strong growth of +18.1% year-over-year. The most recent quarter (Q4 2025) recorded $57.8 million in revenue, down 39.0% sequentially.
Looking at the longer-term picture, STAA's 5-year compound annual growth rate (CAGR) stands at +7.9%, indicating steady revenue expansion. The company achieved its highest annual revenue of $322.4 million in 2023.
Revenue diversification analysis shows STAA's business is primarily driven by Implantable Collamer Lenses (100%), and Other Surgical Products (0%). With over half of revenue concentrated in Implantable Collamer Lenses, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ALGN (+2.9% YoY), LNTH (+0.6% YoY), and TMDX (+30.2% YoY), STAA has underperformed the peer group in terms of revenue growth. Compare STAA vs ALGN →
STAA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| STAACurrent | $239M | +18.1% | +7.9% | -19.2% | |
 ALGN | $4.0B | +2.9% | +10.3% | 15.3% | |
 LNTH | $1.5B | +0.6% | +35.3% | 20.2% | |
 TMDX | $605M | +30.2% | +88.2% | 17.9% | |
 EW | $6.1B | +11.2% | +6.7% | 27.0% | |
 HOLX | $4.1B | +2.2% | +1.7% | 17.4% |
STAA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $239.4M | -23.7% | $176.9M | 73.9% | $-45,872,000 | -19.2% |
| 2024 | $313.9M | -2.6% | $239.6M | 76.3% | $-12,611,000 | -4.0% |
| 2023 | $322.4M | +13.4% | $252.7M | 78.4% | $28.1M | 8.7% |
| 2022 | $284.4M | +23.4% | $223.4M | 78.5% | $43.8M | 15.4% |
| 2021 | $230.5M | +41.0% | $178.6M | 77.5% | $33.3M | 14.5% |
| 2020 | $163.5M | +8.8% | $118.4M | 72.4% | $6.8M | 4.1% |
| 2019 | $150.2M | +21.2% | $112.0M | 74.5% | $11.9M | 7.9% |
| 2018 | $124.0M | +36.8% | $91.5M | 73.8% | $6.6M | 5.3% |
| 2017 | $90.6M | +9.9% | $64.3M | 70.9% | $-3,631,000 | -4.0% |
| 2016 | $82.4M | +6.9% | $58.4M | 70.8% | $-12,655,000 | -15.4% |
See STAA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs STAA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare STAA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSTAA — Frequently Asked Questions
Quick answers to the most common questions about buying STAA stock.
Is STAA's revenue growth accelerating or slowing?
STAA revenue is accelerating at +18.1% year-over-year, exceeding the 5-year CAGR of +7.9%. TTM revenue reached $239M. Growth momentum has increased versus prior periods.
What is STAA's long-term revenue growth rate?
STAAR Surgical Company's 5-year revenue CAGR of +7.9% reflects the sustained expansion pattern. Current YoY growth of +18.1% is above this long-term average.
How is STAA's revenue distributed by segment?
STAA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.